A

Adverum Biotechnologies
D

ADVM

2.85000
USD
0.07
(2.52%)
مغلق
حجم التداول
1,308
الربح لكل سهم
-7
العائد الربحي
-
P/E
-0
حجم السوق
59,538,589
أصول ذات صلة
A
ALLO
0.03500
(3.27%)
1.10500 USD
BMRN
BMRN
-0.470
(-0.81%)
57.530 USD
C
CRSP
0.853
(1.45%)
59.683 USD
E
EDIT
0.08000
(2.70%)
3.04000 USD
N
NTLA
0.090
(0.83%)
10.995 USD
REGN
REGN
14.73
(2.60%)
580.63 USD
S
SGMO
0.02420
(4.37%)
0.57800 USD
S
SRPT
1.500
(7.39%)
21.810 USD
V
VYGR
0.01000
(0.27%)
3.74000 USD
المزيد
الأخبار المقالات

العنوان: Adverum Biotechnologies

القطاع: Healthcare
الصناعة: Biotechnology
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.